Faruqi & Faruqi, LLP is Investigating Pain Therapeutics Inc. on Behalf of its Shareholders (PTIE)
Faruqi & Faruqi, LLP, a national law firm concentrating on investor rights, consumer rights and the enforcement of federal antitrust laws, is investigating potential wrongdoing at Pain Therapeutics Inc. (“PTIE” or the “Company”) (Nasdaq: PTIE). The investigation focuses on whether certain executive officers and directors of PTIE breached their fiduciary duties by releasing false and misleading statements regarding its lead drug, REMOXY, and the likelihood that REMOXY would be approved by the Food and Drug Administration (“FDA”). REMOXY is marketed as a strong painkiller with a unique formulation designed to reduce potential risks of unintended use.
Specifically, the investigation concerns possible breaches of fiduciary duties by the Company’s executive officers and directors for failing to disclose that REMOXY was not approvable by the FDA due to chemistry, manufacturing and control deficiencies that caused inconsistent results during laboratory tests of REMOXY. On June 24, 2011, the Company announced that a Complete Response Letter was received from the FDA rejecting the Company’s New Drug Application (“NDA”) for REMOXY. To date, a new NDA for REMOXY has not been submitted to the FDA nor has the Company meaningfully updated investors regarding any plan to do so.
If you hold PTIE shares and you would like to discuss your legal rights, contact us by calling Beth Keller toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to firstname.lastname@example.org.
Please tell us about yourself by completing the form below and we will provide you with additional
information on how to join the Action.
* The submission of this form does not create an attorney-client relationship.
Faruqi & Faruqi, LLP
685 Third Avenue 26th Floor
New York, NY 10017
Tel: (212) 983-9330
If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.